Lee Jackson
9 min read
Quick Read
-
Pfizer and Bristol-Myers Squibb kept their dividends intact despite market pessimism, with both trading near 9 times forward earnings while new drugs offset fading products.
-
T. Rowe Price carries no significant long-term debt, so no lender can force a dividend decision even as analysts withhold every buy rating.
-
UPS pays out about 89% of expected free cash flow in dividends, leaving thin coverage that depends on continued margin gains.
-
Released: The Definitive Guide to Retirement Income. It is a free guide from Fisher Investments covering what your retirement will really cost, where the cash flow should come from, and how much you can safely withdraw each year. Learn more here. Learn More Here › (sponsor)
When a stock falls out of favor, the balance sheet decides what happens to your income. A company with manageable debt and steady cash flow can keep paying shareholders while it repairs the business. An overleveraged one cuts the dividend to survive (we laid out the seven warning signs that a big yield is about to be cut in a free guide here: Dividend Traps). The four names below have all been marked down by the market or by analysts, and all four have kept their payouts intact. T. Rowe Price Group (NASDAQ:TROW) shows how deep the pessimism runs. Its shares are down 36.94% over five years, even though the company carries no significant long-term debt.
Pfizer: Ultra-High Yield Backed by a Raised Outlook
Pfizer (NYSE:PFE) is the large-cap drugmaker behind Eliquis, Padcev and the Vyndaqel family. The market has turned against it. Shares trade at $27.69, down 28.51% over five years and 6.69% in the past month. Analysts are lukewarm: 17 rate it a hold, against 1 strong buy and 8 buys. The stock trades at a forward P/E of about 9.
——
Now Available: The Definitive Guide to Retirement Income
Many successful investors eventually reach the same moment. The saving is done, the portfolio is built, and the question quietly changes from how much can I grow this to how much can I take out? Get that second question wrong and decades of good investing can come apart in a handful of years.
That is exactly what The Definitive Guide to Retirement Income helps answer. It covers what your retirement could actually cost, which income sources are worth using, and the withdrawal math that decides whether the money lasts. It is free today from Fisher Investments. Read More Here ›
——
Balance sheet read: Debt to equity is 0.78, net debt to EBITDA is 2.76, and interest coverage is 6.52x. Pfizer has made no share repurchases this year, leaving $3.3 billion of authorization untouched while it keeps paying down debt. That ordering puts debt reduction and the dividend ahead of buybacks.